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Abstract: The p21 activated kinase-1 (Pak1) is a serine-threonine protein kinase directly 
activated by Cdc42 and Rac1. In cardiac myocytes, Pak1 activation leads to dephosphorylation 
of cTnI and C-protein through upregulation of phosphatase-2A (PP2A). Pak1 activity is directly 
correlated with its autophosphorylation, which occurs upon binding to the small GTPases and 
to some small organic molecules as well. In this report, we describe a novel method for rapid 
puriﬁ  cation of endogenous Pak1 from bovine ventricle muscle. The method is simple and easy 
to carry out. The puriﬁ  ed Pak1 demonstrated autophosphorylation in vitro that was enhanced 
by D-erythro-sphingosine-1, N-acetyl-D-erythro-sphingosine (C2-ceramide), and N-hexanoyl-
D-erythro-sphingosine (C6-ceramide). Dihydro-L-threo-sphingosine (saphingol) also had some 
effect on Pak1 autophosphorylation. The method we developed provides a useful tool to study 
Pak1 activity and regulation in the heart. Moreover, our results indicate a potential role of the 
sphingolipids as unique signaling molecules inducing a direct activation of Pak1 that may 
modulate different cardiac functions.
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Despite strong evidence indicating an important role of p21 activated kinase (Pak) in 
various tissues, detailed understanding of its signaling mechanisms remains poorly 
understood (Zhao and Manser 2005). An important step in identifying these mecha-
nisms is the development of methods for puriﬁ  cation of the enzyme. We describe here 
a novel approach that we developed for isolation of Pak1 from ventricular myocardium, 
which will also be useful in other tissues.
Pak1 belongs to a family of serine/threonine protein kinases directly activated by 
small GTPases, Cdc42 and Rac1. In the heart, Pak1 is abundant and localizes to cell 
and nuclear membranes, intercalated discs and to Z-discs in ventricular myocytes. 
The active form of Pak1 in cardiomyocytes increases Ca2+ sensitivity of myoﬁ  lament 
force development through activation of PP2A (Ke et al 2004) and in SA nodal cells, 
Pak1 inhibits isoproterenol stimulated activation of L-type Ca2+ channel and delayed 
rectiﬁ  er potassium channels (Ke et al 2007a). Other studies have shown that in endo-
thelial cells, Pak1 activation induces dephosphorylation of myosin regulatory light 
chain and inhibition of thrombin-induced barrier dysfunction (Ke et al 2007b) and 
in HeLa cells, expression of constitutively active Pak1 induces loss of stress ﬁ  bers 
and dissolution of focal adhesion complexes (Manser et al 1997). These studies sug-
gest a role of Pak1 in cytoskeletal function and reorganization. In transgenic mice 
expressing an active Rac1 in the heart, hypertrophy developed followed by dilated 
cardiomyopathy with altered intracellular partitioning of Pak1 in the ventricle myocytes 
(Sussman et al 2000).Biologics: Targets & Therapy 2008:2(4) 904
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A prominent post-translational modiﬁ  cation of Pak1 is 
autophosphorylation, which is correlated with its activity 
(Manser et al 1997; Zhao et al 1998). Pak1 is autophosphory-
lated at seven serine/threonine sites most of which occur at 
the N-terminal half of the kinase. Substitution of threonine 
423, the last autophosphorylation site, with glutamic acid 
renders the kinase constitutively active (Manser et al 1997). 
Although there is abundant expression of Pak1 in cardiomyo-
cytes, smooth muscle and endothelial cells, the function of 
Pak1 in the cardiovascular system remains poorly understood 
(Sheehan et al 2007). Moreover, potential modiﬁ  cations in 
autophosphorylation of native Pak1 in failing heart and in 
other pathological conditions have not been deﬁ  ned.
Studies in skeletal muscle have shown that Pak1 activity 
was responsive to insulin treatment (Tsakiridis et al 1996) 
suggesting that Paks are also phosphorylated by tyrosine 
kinase (Bagheri-Yarmand et al 2001; He et al 2004; Yang 
et al 2004). Tyrosine phosphorylation of Pak1 may also play 
an important role in regulation of cardiac function. However, 
little is known about any tyrosine kinase signaling mecha-
nism that may play a role in Pak activity.
In order to further study Pak1 function in the heart, we 
developed a novel afﬁ  nity chromatography method to purify 
endogenous Pak1 from heart muscle homogenate. A synthetic 
peptide derived from Pak1 protein with an HA tag that binds 
to HA matrix speciﬁ  cally retains Pak1 in the matrix and thus 
enriches Pak1 from tissue homogenate. A clear, single Pak1 
protein band was detected from the eluant. The puriﬁ  ed Pak1 
demonstrated autophosphorylation that was stimulated by 
sphingosine and sphingosine derivatives.
Methods
Preparation of muscle sample
Frozen bovine ventricle muscle (200 g) was cut into small 
pieces and homogenized in a blender containing 1 liter 
homogenization buffer (50 mM Tris base, 5 mM EDTA, 
2 mM EGTA, 1 mM DTT, 0.5 mM benzamidine, 0.1 mM 
PMSF, pH 7.2). The homogenized muscle sample was centri-
fuged at 4500 g for 30 minutes. The supernatant fraction was 
saved and precipitated with ammonium sulfate (NH4)2SO4 
at concentration 25% and 50% (w/v). Precipitates formed 
by (NH4)2SO4 addition between concentration 25% (w/v) 
and 50% (w/v) were saved and dialyzed against the homog-
enization buffer. After dialysis, the sample was ﬁ  ltered and 
lyophilized. For puriﬁ  cation of Pak1 from smaller amounts 
of sample, the tissues or cells were homogenized in mam-
malian extraction buffer (50 mM Tris, pH 7.5; 150 mM NaCl; 
0.1% Nonide P40; Complete Protease inhibitor cocktail 
tablets [Roche Diagnostics, cat # 11 873 580 001]). The 
ratio of tissue:buffer was about 1:5 (v/v). The homogenate 
was centrifuged in a bench-top centrifuge at 4 °C. The 
supernatant fraction was saved for direct application onto 
the afﬁ  nity column.
Peptide synthesis and the matrix
The peptides were synthesized in the University of Illinois 
at Chicago protein core facility. The decoy peptide 
(YNSKKTSNSQKYMSFTDKSAYPYDVPDYA) contained 
the Pak1 sequence from amino acids 131 to 150 linked to a 
9 amino acid of inﬂ  uenza hemagglutinin (HA) epitope. The 
peptide derived from the N-terminal region of Pak1 with the 
sequence MSNNGLDIQDKPPAPPMRNTSTYPYDVPDYA 
was also used in some puriﬁ  cation. The Anti-HA Afﬁ  nity 
Matrix (Cat. No. 1 815 016) was purchased from Roche 
Applied Science (Indianapolis, IN, USA). The affinity 
matrix contains antibody speciﬁ  cally bind to HA sequence 
in protein or peptide.
Afﬁ  nity chromatography
The column was ﬁ  rst washed with 20 ml equilibration buffer 
(20 mM Tris, pH 7.5; 0.1 M NaCl; 0.1 mM EDTA). Decoy 
peptide (3 mg) was applied to the column to saturate the 
matrix with the peptide. The muscle sample (the lyophilized 
extract) was dissolved in buffer (20 mM Tris, pH 7.5; 0.1 M 
NaCl; 0.1 mM EDTA) containing protease inhibitor cocktail 
tablets. The sample was loaded onto the afﬁ  nity column 
and then washed with 20 ml washing buffer (20 mM Tris, 
pH 7.5; 0.1 M NaCl; 0.1 mM EDTA; 0.05% Tween-20). The 
Pak1 bound to the gel was eluted with equilibration buffer 
containing HA peptide (YPYDVPDYA) at 1 mg/ml. HA 
peptide was removed from the sample by dialysis in buffer 
containing 20 mM HEPES, 5 mM NaCl, pH 7.2. The bound 
Pak1 could also be eluted with 5 ml glycine buffer, pH 2.5 
(50 mM glycine-HCl; 0.1 % Triton X-100; 0.15 M NaCl).
Kinase assay
Pak1 kinase activity was assayed in the following reaction 
buffer: 50 mM HEPES, pH 7.3, 10 mM MgCl2, 1 mM DTT, 
0.05% Triton X-100) with 10 μCi of [γ32P] ATP (Perkin 
Elma. [γ-32P]-Adenosine 5`-triphosphate, Speciﬁ  c Activity: 
3000Ci (111TBq)/mmole, 50 mM Tricine (pH 7.6), Con-
centration: 5 mCi/mL, Catal NEG502H250UC) at 37 °C 
for 2 h. The kinase reaction was stopped by adding SDS 
sample buffer followed by boiling for 5 min. Agonists added 
to the buffer were as described in the Results section and 
the ﬁ  gure legends. Agonists from Calbiochem included the Biologics: Targets & Therapy 2008:2(4) 905
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following: C2 ceramide (N-acetyl-D-erythro-sphingosine), 
C6 ceramide (N-Hexanoyl-D-erythro-sphingosine) and saﬁ  n-
gol (Dihydro-L-threo-sphingosine). D-sphingosine (S 6879), 
and sphingosine 1-phosphate (S 9666) were purchased from 
Sigma (St. Louis, MO, USA). Sphingosines were dissolved 
in dimethyl sulfoxide. The total reaction volume was 20 μl. 
Dimethyl sulfoxide (2 μl) was included in each reaction 
including the control.
Results
Cellular localization and puriﬁ  cation 
of Pak1
Figure 1 show results of immuno-histochemical studies in 
rat ventricular myocytes demonstrating high and localized 
expression of Pak1. The bleb in the image of Figure 1A 
(upper panel) indicates sarcolemmal localization. Pak 1 also 
localized to the nuclear membrane, Z-discs and intercalated 
discs (Figure 1A). To isolate the cardiac Pak1, we used bovine 
ventricle muscle as the source as described in the Methods. 
About 800 mg of muscle protein extract was obtained from 
200 g of the frozen ventricle muscle. Therefore, the yield of 
muscle extract from the frozen tissue is about 0.4%. Figure 1B 
illustrates the approach we used for afﬁ  nity puriﬁ  cation of the 
Pak1 as described in the Methods. The peptide linked afﬁ  nity 
column was loaded with 5 mg of the protein extracted from 
the muscle sample. Data in Figure 2A demonstrate that Pak1 
is the major component in the eluted fraction as indicated by 
the resolution of the samples by SDS-PAGE with Coomassie 
brilliant blue staining (Figure 3A, lane 3). Ammonia sulfate 
fractionation decreased amount of some proteins with the 
molecular weight larger and smaller than Pak1 (Figure 3A). 
Western blotting analysis (Figure 2B) using an antibody 
(sc-881) identiﬁ  ed the bands shown in Figure 2A as Pak1. 
The afﬁ  nity puriﬁ  cation procedure yielded about 200 μg of 
total protein from the 5 mg muscle protein extract prepared 
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Figure 1 A. Pak1 is abundant and has deﬁ  ned intracellular localizations in adult rat ventricle myocytes. Localization and expression of Pak1 in rat ventricle myocytes were detected 
by immuno-ﬂ  uorescence and confocal microscopy. Pak1 was stained with ﬂ  uorescein Isothiocyanate (FITC) (green).   Actin was stained with phalloidin (red). Pak1 is localized to 
the Z-discs (indicated by the yellow stripes showing overlap of the red and green stains), intercalated discs, nuclear and cell membranes and at the sarcolemmal membrane as 
emphasized by a bleb in the bottom panel.   The myocytes were isolated from rat ventricle as described previously (Ke et al 2004). B. Schematic representation of puriﬁ  cation 
of Pak1 from cardiac muscle. The puriﬁ  cation procedure can be divided into three steps. Step 1.   The decoy peptide derived from Pak1 autoinhibitory region linked to inﬂ  uenza 
hemagglutinin (HA) epitope was bound to HA matrix. Step 2. Pak1 was bound to the peptide. The matrix was washed with washing buffer. Step 3.   The peptide was eluted out 
from the matrix by glycine at pH 2.5 or by HA peptide. See text for details. C.   The decoy peptide is derived from the autoinhibitory region of Pak1.  The autoinhibitory domain 
of Pak1 is downstream of p21 binding domain (PBD) and by dimerization domain (DI).   The vertical bars represent the proline rich sequences in Pak1.Biologics: Targets & Therapy 2008:2(4) 906
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Figure 3 A. Autophosphorylation of Pak1 is stimulated by sphingosine-phosphate in vitro.   The in vitro reaction was carried out at 37 °C for two hours.   The same amount of 
Pak1 protein (4 μg) was included in each reaction. Sphingosine phosphate was added to each reaction at concentrations 0, 25, 50, 100, and 200 μM. B. Autophosphorylation of 
Pak1 is stimulated by D-erythro-sphingosine in vitro.   The in vitro reaction was carried out at 37 °C for two hours. 4 μg of Pak1 protein was included in each reaction. Increasing 
amounts of D-erythro-sphingosine were added at 0, 25, 50, 100, and 200 μM.   The smaller band below 68 kD Pak1 signal is about 48 kD and is a Pak1 degradation product.
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Figure 2 Puriﬁ  ed native Pak1 From cardiac muscle. A. Puriﬁ  cation of endogenous Pak1 from cardiac muscle. 1. Cardiac muscle extracts resolved on a SDS page. 2. The 
cardiac muscle extract after fractionation by 25% and 50% (NH4)2SO4 precipitation. 3. Pak1 puriﬁ  ed from the fractionated muscle sample. 4. The molecular weight markers. 
B. Detection of puriﬁ  ed Pak1 by Western blotting analysis. Pak1 was detected as a single band with an antibody from Santa Cruz (sc-881). C. Puriﬁ  ed Pak1 detected by mass 
spectrometry. Peaks match the Pak1 peptides produced by theoretical trypsin digestion. The positions of amino acids of each peptide from Pak1 were denoted in quotation: 
LSAIFR (490–495), ELLQHQFLK (514–522), SVIEPLPVTPTR (204–215), KELIINEILVMR (309–320), ECLQALEFLHSNQVIHR (372–388).Biologics: Targets & Therapy 2008:2(4) 907
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from the frozen ventricle with a yield of 4%. Therefore, the 
yield of ﬁ  nal afﬁ  nity puriﬁ  cation product from the frozen 
ventricle is about 0.016% (w/w). Pak1 bound to the matrix 
was eluted with 3 mg of HA peptide that displace the decoy 
peptide from the matrix. The HA peptide in the eluant was 
separated from Pak1 protein by use of dialysis tubing per-
meable to proteins smaller than 12–14 kD (Figure 1B). The 
bound Pak1 can also be eluted with Glycine (0.1 M, pH2.0). 
However, elution with glycine sometimes produces an extra 
protein bands with molecular weight of 16 kD. Mass spec-
trometry analysis indicated that the major MS peaks from the 
digested protein puriﬁ  ed matches with Pak1 peptides after 
trypsin digestion (Figure 2C).
In vitro autophosphorylation
Autophosphorylation of Pak1, which correlates with its activ-
ity and that we assessed with an in vitro assay, provided a 
measure of Pak-1 enzyme function. Initial studies (data not 
shown) indicated that autophosphorylation of the wt Pak1 
was much weaker than the constitutively active Pak1 as 
shown by others (Manser et al 1997). In all the in vitro assays, 
we used 4 μg of Pak1 protein. The smaller band (∼48 kD) that 
could be Pak1 degradation products was also phosphorylated. 
The puriﬁ  ed Pak1 also demonstrated kinase activity towards 
the decoy peptide (YNSKKTSNSQKYMSFTDKSA). The 
decoy peptide contains Pak1 autophosphorylation sites. 
The two serine residues that are autophosphorylated are 
situated at the end of the autoinhibitory sequence. The decoy 
peptide slightly inhibited autophosphorylation of Pak1. 
However, it was also phosphorylated and there was a slight 
increase of the total kinase activity in the presence of the 
decoy peptide (data not shown).
In view of data reporting a sphingosine-1 induced increase 
in Pak1 and Pak2 activity in vitro (Bokoch et al 1998; Roig 
et al 2001), we also tested the effect of sphingosine and 
sphingosine-1 phosphate on Pak1 autophosphorylation 
(Figure 3A). Incorporation of 32P from gamma 32P into 
Pak1 was directly detected by autoradiography after resolving 
the in vitro reaction products on SDS PAGE. Interestingly, 
sphingosine-1 phosphate had no signiﬁ  cant effect on auto-
phosphorylation of Pak1 at 25 and 50 μM. When the sphin-
gosine phosphate concentration increased to 100 and 200 μM, 
there was an increase in Pak1 autophosphorylation. In puriﬁ  ed 
Pak1 sample, a 48 kD Pak1 degradation products can some-
times be detected (Figure 1A, lane 3). When Pak1 activity 
increased, phosphorylation of the degradation products 
increased accordingly (Figure 3). Our results indicated that 
autophosphorylation of Pak1 puriﬁ  ed from cardiac muscle was 
highly responsive to C2 and C6 ceramide (Figure 4A and B). 
Autophosphorylation of the puriﬁ  ed Pak1 increased in the 
presence of 50 and 100 μM of D-sphingosine-1 (Figure 3B), 
but saphingol (dihydro-L-threo-sphingosine) only slightly 
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Figure 4 A and B. Autophosphorylation of Pak1 is stimulated by C2 (left) and C6 ceramide (right) in vitro. C2 and C6 ceramide was added to the reaction at different 
concentrations at 0, 50, 100, and 200 μM. Pak1 protein (4 μg) was included in each reaction. In C, autophosphorylation of Pak1 is regulated to a lesser extent by saphingol 
(dihydro-sphingosine). Saphingol was added to each reaction at concentrations of 0, 25, 50, 100, and 200 μM.Biologics: Targets & Therapy 2008:2(4) 908
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regulated Pak1 autophosphorylation (Figure 4C). By gel 
ﬁ  ltration, the puriﬁ  ed Pak1 demonstrated a single major peak. 
The same experiments were repeated three times each.
Discussion
Our data demonstrating a simple method for purifying native 
Pak1 from cardiac muscle provide signiﬁ  cant new informa-
tion important in advancing understanding of the Pak-1 
signaling in the heart. Moreover, to our knowledge, our data 
also provide the ﬁ  rst evidence demonstrating regulation of the 
activity of Pak1 by C2 and C6 ceramide. Our understanding 
of Pak1 function in myocardial cells is still in its infancy, 
and we think the method reported here is an important step 
in deﬁ  ning these functions and their mechanisms. Signal-
ing molecules such as Pak1 are often extensively modiﬁ  ed 
by post-translational mechanisms, and in many cases these 
modiﬁ  cations are associated with pathophysiological condi-
tions. Our method is suitable for study of post-translational 
modiﬁ  cations of Pak1 in response to different extracellular 
signals and in pathological conditions such as heart failure, 
arrhythmias, and ischemia. The Pak1 kinase puriﬁ  ed by this 
method can also be used for in vitro kinase assay to identify 
novel activators or inhibitors. Moreover, the method can be 
adapted for use in puriﬁ  cation of Pak isoforms from mam-
malian tissues other than heart.
The puriﬁ  ed Pak1 retained low catalytic activity as dem-
onstrated by autophosphorylation in vitro. The constitutively 
active Pak1 (T423E) has a much higher level of autophos-
phorylation than the endogenous Pak1 under the same con-
ditions. We found that autophosphorylation of the puriﬁ  ed 
Pak1 is enhanced by D-sphingosine-1, N-acetyle-sphingosine 
(C2 ceramide) and by hexanoyl-sphingosine (C6 ceramide). 
This is consistent with an earlier observation that the activi-
ties of Pak1 and Pak2 are activated by sphingosine (Bokoch 
et al 1998; Roig et al 2001). Our ﬁ  nding that active Pak1 
induces dephosphorylation of cTnI and C-protein through 
activation of PP2A (Ke et al 2004) provides a plausible 
mechanism for induction of protein dephosphorylation by 
sphingosine. For example, C2-ceramide is a known activator 
of PP2A (Dobrowsky et al 1993) and may be involved in Bcl2 
dephosphorylation (Ruvolo et al 1999). In different types of 
cells, L-type Ca2+ channel activity was demonstrated to be 
depressed by C2 ceramide by an unknown mechanism (Chik 
et al 1999, 2004). C2 ceramide also inhibited proliferation of 
T-cells stimulated by growth signals (O’Byrne and Sansom 
2000). Moreover, C2 ceramide has preconditioning effects 
in heart, which has been attributed to generation of reac-
tive oxygen species (Furuya et al 2001; Lecour et al 2006). 
Our data indicate that other mechanisms for C2 ceramide 
involving activation of Pak1 and PP2A need to be consid-
ered. To our knowledge, this is the ﬁ  rst time demonstration 
that Pak1 is directly stimulated by C2 and C6 ceramide. 
The mechanism whereby Pak1 is activated by sphingosine 
analogs is still not clear. Our studies indicate that C2 and C6 
ceramide had stronger effect than sphingosine-1 activating 
Pak1. Saphingosine only had a small stimulatory effect on 
Pak1 autophosphorylation. Zenke and colleagues (1999) 
suggest that sphingosine activates Pak through the P21 bind-
ing domain (PBD). However, in another study, Cdc42 and 
sphingosine-1 appears to have a cooperative effect activating 
the kinase (Chong et al 2001). We plan to employ a molecular 
biology approach to map the amino acid sequence on Pak1 
that interacts with sphingosines.
The peptide used to decoy native Pak1 from cardiac 
muscle is derived from the autoinhibitory region of Pak1 
(Manser et al 1997) (Figure 1C). The autoinhibitory region 
is both downstream of and partially overlaps with the P21 
binding domain (PBD) (Zhao et al 1998). A peptide derived 
from the N-terminal region (the ﬁ  rst 21 amino acids of Pak1) 
that binds to Nck in vitro (Bokoch et al 1998; Zhao et al 
2000) also efﬁ  ciently retained Pak1 in the column (data not 
shown). The peptide interacts with the catalytic center of the 
kinase and may regulate the conformation of the catalytic 
center as demonstrated by NMR studies (Pirruccello et al 
2006). Expression of the peptide plus the P21 binding region 
produced many cellular changes including inhibition of cell 
cycle progression (Thullberg et al 2007). The autoinhibitory 
region was also deleted in GST-Pak1 which was used for in 
vitro kinase studies (Polverino et al 1995).
Pak1 is autophosphorylated at multiple serine/threonine 
sites. There are at least six autophosphorylation sites at 
the N-terminal half of Pak1 (Manser et al 1997). Auto-
phosphorylation at the N-terminus of Pak1 may change its 
intracellular localization or/and activity (Zhao and Manser 
2005). It is unclear at which site autophosphorylation occurs 
ﬁ  rst in the activation of Pak1. Furthermore, uncertainty still 
remains as to whether autophosphorylation is through inter- 
or intramolecular kinase reactions. Since Pak1 dimer has an 
antiparallel conformation, autophosphorylation sites at the 
N-terminal half of one Pak1 are therefore placed in proximity 
to the catalytic domain of the other Pak1 (Lei et al 2000). 
This suggests that intermolecular autophosphorylation may 
occur at the N-terminal autophosphorylation sites.
Pak1 contains a few proline-rich sequences at its 
N-terminus. The proline-rich sequences interact with pro-
teins, such as Nck and Pix. A prominent feature of these Biologics: Targets & Therapy 2008:2(4) 909
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proline-rich sequences in Pak1 is that they are followed 
by autophosphorylation sites. Peptide decoy was first 
designed to identify proteins that interact with the proline 
rich sequences in the heart. It turned out Pak1 is the only 
major protein that binds to the decoy peptides, including 
the peptide containing 22 amino acids (MSNNGLDIQD-
KPPAPPMRNTST) at the N-terminal region of the kinase 
which contains an autophosphorylation site at Serine 21. 
Substitution of the serine residue for aspartic acid abolished 
Nck binding to the peptide in vitro (Zhao et al 2000). In vivo, 
phosphorylation at the autophosphorylation sites could be a 
mechanism to release the “autosubstrate” from the catalytic 
center of the kinase.
Interaction between lipids and a protein kinase may have 
profound effect on cellular functions (Argraves et al 2002). 
The puriﬁ  ed Pak1 is stimulated by more than one sphingosine 
species. It is likely that some other sphingosine related lipids 
may also regulate Pak1 activity. Modiﬁ  cation of the side 
chain and the polar groups of sphingosines may produces 
agonists or antagonists that have even more potent effect on 
Pak1 autophosphorylation.
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